generation run 2026-05-03
59 min completedmodel pipeline-v5plan not recordedrun/5aa7fab1…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- editorial_note
Reproduce
- inputs
- 33 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubChem | dextroamphetamine | 1 | 1 | Confirmed all key chemical identity fields absent from brief seed data |
| 2 | PubMed | dextroamphetamine pharmacokinetics bioavailability half-life metabolism humans | 2 | 1 | — |
| 3 | PubMed | amphetamine VMAT2 vesicular monoamine transporter mechanism dopamine release | 8 | 3 | — |
| 4 | PubMed | dextroamphetamine receptor binding affinity dopamine norepinephrine pharmacology | 2 | 0 | — |
| 5 | PubMed | amphetamine cardiovascular effects blood pressure heart rate hypertension | 8 | 2 | — |
| 6 | ClinicalTrials.gov | dextroamphetamine | 15 | 3 | Directly dextroamphetamine-specific trials; others were lisdexamfetamine |
| 7 | OpenAlex | dextroamphetamine amphetamine mechanism action dopamine releasing agent | 10 | 2 | — |
| 8 | PubMed | amphetamine narcolepsy treatment | 7 | 1 | — |
| 9 | PubMed | amphetamine monoamine transporter DAT NET SERT releasing agent mechanism | 4 | 3 | — |
| 10 | PubMed | dextroamphetamine ADHD clinical trial efficacy | 10 | 1 | — |
| 11 | WebSearch | dextroamphetamine DEA Schedule II legal status US UK Australia Canada controlled substance | 10 | 2 | Legal status data needed for article, not available in PubMed |
| 12 | WebSearch | Lazar Edeleanu amphetamine 1887 Gordon Alles 1927 history discovery | 10 | 3 | Historical discovery timeline |
| 13 | PubMed | amphetamine neurotoxicity serotonin dopamine terminal oxidative reactive species | 3 | 1 | — |
| 14 | WebSearch | dextroamphetamine pharmacokinetics half-life bioavailability FDA prescribing information | 10 | 1 | Primary pharmacokinetic data from official FDA label |
| 15 | OpenAlex | Rothman Baumann amphetamine monoamine release rat brain synaptosome 2001 | 5 | 1 | — |
| 16 | StatPearls NCBI NBK507808 | — | 1 | 1 | Comprehensive clinical reference synthesizing FDA label and published data |
| 17 | WebSearch | amphetamine tramadol serotonin syndrome fatal interaction mechanism | 10 | 1 | Needed to investigate 'lethal' interaction label in brief between tramadol and dextroamphetamine |
| 18 | PubMed | PMID 16515684 | 1 | 1 | Key binding affinity data for dextroamphetamine |
| 19 | Release UK | — | 1 | 1 | — |
| 20 | PubMed | Cortese 2018 network meta-analysis pharmacological treatment ADHD | 3 | 4 | Key efficacy evidence for dextroamphetamine in ADHD from high-quality systematic reviews |
| 21 | WebSearch | amphetamine WWII military RAF Benzedrine alertness | 10 | 1 | — |
| 22 | WebSearch / CCSA Canada | dextroamphetamine Canada CDSA Schedule | 10 | 1 | — |
| 23 | ADF Australia | — | 1 | 3 | — |
64 claims by section — every cited sentence, checked against its source
pharmacology13 · 11 ok
Dextroamphetamine exerts its primary pharmacological effects through three mechanistically distinct but synergistic actions at monoamine synapses:supported
Stimulants such as amphetamine, MDMA, or mephedrone can act on neuronal membrane monoamine transporters NET, DAT, and SERT and/or VMAT2 to inhibit reuptake or cause release by reverse transport. jcph.1918
Dextroamphetamine exerts its primary pharmacological effects through three mechanistically distinct but synergistic actions at monoamine synapses:supported
Amphetamine is a high-affinity molecular target substrate for DAT, NET, and SERT. Discusses phosphorylation and trafficking regulation. pmid:16353949
Once intracellular, it causes monoamine efflux through carrier-mediated reverse transport, a process mechanistically distinct from reuptake inhibitionsupported
Stimulants such as amphetamine, MDMA, or mephedrone can act on neuronal membrane monoamine transporters NET, DAT, and SERT and/or VMAT2 to inhibit reuptake or cause release by reverse transport. jcph.1918
Once intracellular, it causes monoamine efflux through carrier-mediated reverse transport, a process mechanistically distinct from reuptake inhibitionsupported
S(+)-amphetamine used as reference standard for full substrate/releaser efficacy at hDAT. Provides mechanistic context for amphetamine's DAT activity. j.neuropharm.2023.109704
Intracellularly, d-amphetamine disrupts vesicular monoamine transporter-2 (VMAT2) function, causing redistribution of dopamine from synaptic vesicles into the cytoplasmpartially supported
Cryo-EM structures of human VMAT1 complexed with amphetamine and multiple monoamines. Amphetamine shares binding pocket with monoamines. Explains mechanism of amphetamine-induced monoamine redistribution. s41586-024-07290-7
A 2024 cryo-EM study of human VMAT1 confirmed that amphetamine shares the same substrate binding pocket as dopamine and other monoaminessupported
Cryo-EM structures of human VMAT1 complexed with amphetamine and multiple monoamines. Amphetamine shares binding pocket with monoamines. s41586-024-07290-7
The efflux process requires concerted action at both VMAT2 and DAT and does not require cytosolic Ca²⁺.supported
Amphetamine-induced DA efflux is strictly dependent on concerted action on both VMAT2 and DAT. Does not require cytosolic Ca2+. Blocked by cocaine (DAT inhibition) or reserpine (VMAT2 inhibition). j.jbc.2023.105063
Dextroamphetamine acts as an agonist at trace amine-associated receptor 1 (TAAR1), an intracellular Gs-protein-coupled receptorsupported
Cryo-EM structures of human TAAR1-G-protein complexes with methamphetamine and beta-PEA. TAAR1 recognizes amphetamine and methamphetamine. s41586-023-06775-1
Dextroamphetamine acts as an agonist at trace amine-associated receptor 1 (TAAR1), an intracellular Gs-protein-coupled receptorsupported
Cryo-EM structures of human and mouse TAAR1 with amphetamine and other ligands. Reveals molecular basis of amphetamine recognition by TAAR1 with rigid consensus binding motif. s41586-023-06804-z
TAAR1 activation by intracellular amphetamine triggers downstream signaling cascades including RhoA and CaMKII pathways that induce transporter internalization (endocytosis of DAT and NET), further reducing reuptake capacity and amplifying monoamine effluxpartially supported
Amphetamine causes endocytosis of NET and EAAT3 via intracellular TAAR1 activation and RhoA signaling in norepinephrine neurons. s11064-019-02939-6
Claim in pharmacology — inconclusiveinconclusiveworking →
Progressive depletion of vesicular monoamine stores with repeated dosingsupported
Supports hypothesis that VMAT modulates AMPH-sensitization via redistribution of intraneuronal DA pools. j.brainres.2025.149848
Claim in pharmacology — inconclusiveinconclusiveworking →
neuroscience11 · 8 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Brauer et al. (1997) demonstrated that even high-dose D2 receptor blockade with pimozide fails to completely abolish amphetamine-induced euphoria, suggesting involvement of additional receptor systems (possibly D1 or non-dopaminergic pathways) in the subjective rewarding effects.supported
Pimozide failed to consistently antagonize amphetamine-induced euphoria. pmid:9050084
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Intermittent dosing: Behavioral sensitization — progressive enhancement of locomotor and reinforcing responses — develops through VMAT2 redistribution that amplifies cytoplasmic dopamine availability upon subsequent exposuresupported
Supports hypothesis that VMAT modulates AMPH-sensitization via redistribution of intraneuronal DA pools. j.brainres.2025.149848
Robinson and Becker (1986) characterize sensitization as involving persistent changes in mesolimbic dopamine release dynamics that may persist for months to years after cessation, potentially underlying the chronic relapsing nature of amphetamine addiction.supported
Review of amphetamine neurotoxicity and behavioral sensitization as models of amphetamine psychosis. Sensitization characterized by progressive enhancement of amphetamine-induced behaviors due to enhanced DA release. pmid:3527341
The mechanism involves: (1) excessive cytoplasmic dopamine auto-oxidation producing quinones and free radicals; (2) mitochondrial dysfunction from dopamine-derived oxidative stress; (3) neuroinflammatory cascade via microglial activationpartially supported
Reactive oxygen species and reactive nitrogen species as mediators; covalent modification of TH and TPH. pmid:11085312
Robinson and Becker (1986) proposed that progressive behavioral sensitization to amphetamine models the development of amphetamine psychosis and, by extension, the positive symptoms of schizophreniasupported
Review of amphetamine neurotoxicity and behavioral sensitization as models of amphetamine psychosis. pmid:3527341
Walker-Batson et al. (2001) demonstrated that dextroamphetamine paired with targeted rehabilitation enhances neural plasticity in post-stroke aphasia recoverysupported
Extends prior findings of noradrenergic agonist promoting recovery after brain injury. pmid:11546902
Neurotoxicity threshold in humans: What sustained dose and duration of d-amphetamine exposure produces measurable dopaminergic terminal damage in human striatum? Most data extrapolate from methamphetamine cohorts or animal models.supported
D-amphetamine (along with D-methamphetamine, MDMA, p-chloroamphetamine) causes microglial activation in striatum, linked to dopamine nerve terminal damage. pmid:15337264
Pharmacogenomic dose optimization: Can DAT (SLC6A3) and CYP2D6 genotyping meaningfully predict individual dose requirements and adverse event risk?supported
DAT polymorphism rs460000 C/C genotype showed 2-fold higher ratings of stimulation and euphoria. s10519-009-9331-7
safety10 · 8 ok
The Cochrane systematic review by Chan et al. (2025) identified significant evidence that amphetamines raise blood pressure with chronic daily use, though long-term cardiovascular outcome data remain limitedsupported
Cochrane review: daily ingestion of amphetamines (prescribed for ADHD and other diagnoses) has potential to increase blood pressure; long-term benefit vs. harm remains uncertain. 14651858.cd007896.pub4
Simonds et al. (2025) demonstrated that amphetamine's cardiovascular effects are partially mediated by the central melanocortin system (MC4R pathway), independent of anorectic effects.supported
Amphetamine increases alpha-MSH secretion from hypothalamus, elevates blood pressure/heart rate, increases BAT thermogenesis, reduces food intake. Melanocortin 4 receptor partially mediates these effects. j.xcrm.2025.101936
D-amphetamine at high doses causes microglial activation in the striatum and dopaminergic nerve terminal damage mediated by reactive oxygen species (ROS) and reactive nitrogen species (RNS)supported
D-amphetamine (along with D-methamphetamine, MDMA, p-chloroamphetamine) causes microglial activation in striatum, linked to dopamine nerve terminal damage. pmid:15337264
D-amphetamine at high doses causes microglial activation in the striatum and dopaminergic nerve terminal damage mediated by reactive oxygen species (ROS) and reactive nitrogen species (RNS)supported
D-amphetamine at high doses causes damage to dopamine nerve terminals. Reactive oxygen species and reactive nitrogen species as mediators. pmid:11085312
Thomas et al. (2004) confirmed that d-amphetamine causes this neurotoxicity similarly to methamphetamine and MDMA, distinguishing neurotoxic amphetamine-class compounds from non-neurotoxic memberssupported
D-amphetamine (along with D-methamphetamine, MDMA, p-chloroamphetamine) causes microglial activation in striatum, linked to dopamine nerve terminal damage. Non-neurotoxic amphetamines (l-methamphetamine, fenfluramine, DOI) do not cause this effect. pmid:15337264
Robinson and Becker (1986) describe progressive behavioral sensitization with repeated administration as the mechanistic substrate for psychosis developmentsupported
Sensitization characterized by progressive enhancement of amphetamine-induced behaviors due to enhanced DA release. pmid:3527341
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Paradoxically, intermittent use patterns can produce behavioral sensitization rather than tolerance, mediated through VMAT2 redistribution.supported
Supports hypothesis that VMAT modulates AMPH-sensitization via redistribution of intraneuronal DA pools. j.brainres.2025.149848
McCabe et al. (2005) found 6.9% lifetime prevalence of non-medical prescription stimulant use (including Dexedrine) among US college students, with higher rates in fraternities/sororities and competitive academic environments.supported
6.9% lifetime prevalence of non-medical prescription stimulant use (Ritalin, Dexedrine, Adderall) among US college students. Higher among males, whites, fraternities/sororities members. pmid:15598197
clinical-evidence9 · 6 ok
The dextroamphetamine transdermal system (d-ATS) demonstrated efficacy in a Phase 2 randomized controlled trial (Cutler et al. 2022) in children and adolescents aged 6–17, with significant ADHD symptom reduction at patch doses of 5–20 mg measured by the SKAMP scale.supported
Phase 2 RCT of d-ATS patches (5-20 mg) vs placebo in children/adolescents 6-17 with ADHD. Significant improvement in SKAMP scores. cap.2021.0107
Controlled human laboratory studies at 10 and 20 mg oral doses have characterized dose-response relationships for subjective, cognitive, and cardiovascular outcomes.supported
N=152 healthy volunteers received placebo, 10 mg, and 20 mg d-amphetamine... Provides dose-response and subjective effects data for d-amphetamine in healthy subjects. s10519-009-9331-7
Controlled human laboratory studies at 10 and 20 mg oral doses have characterized dose-response relationships for subjective, cognitive, and cardiovascular outcomes.supported
N=12 normal volunteers given d-amphetamine (10 and 20 mg) and pimozide (8 mg). D-amphetamine produced significant effects on Elation and Vigor ratings. pmid:9050084
Amphetamines demonstrated the highest efficacy for ADHD symptom reduction in children and adolescents among all pharmacological interventions studied, and were among the most efficacious in adults.supported
Amphetamines were most efficacious for children/adolescents... Amphetamines showed largest effect sizes for ADHD symptom reduction across age groups. s2215-0366(18)30269-4
Farhat et al. (2024) conducted a systematic review and meta-analysis in JAMA Psychiatry examining licensed versus unlicensed stimulant doses for adult ADHD, providing dose-optimization data for clinical practicesupported
Meta-analysis examining dose escalation beyond FDA recommendations for adult ADHD. Provides data on licensed dose ranges for amphetamines in adults. jamapsychiatry.2023.3985
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Trotti et al. (2024) conducted the first randomized, blinded, non-inferiority trial directly comparing modafinil versus amphetamine-dextroamphetamine for narcolepsy type 2 and idiopathic hypersomniasupported
Randomized non-inferiority trial comparing modafinil vs amphetamine-dextroamphetamine in narcolepsy type 2 and idiopathic hypersomnia. s40263-024-01122-y
Claim in clinical-evidence — inconclusiveinconclusiveworking →
summary7 · 7 ok
It is one of the most extensively studied psychostimulants in medicine — the 2018 Cortese network meta-analysis of 133 RCTs identified amphetamines as the most efficacious pharmacological intervention for ADHD symptom reduction in children and adolescents.supported
Network meta-analysis of ADHD medications. Amphetamines were most efficacious for children/adolescents; methylphenidate was best tolerated. Amphetamines showed largest effect sizes for ADHD symptom reduction across age groups. s2215-0366(18)30269-4
Dextroamphetamine functions as a substrate-type releasing agent at the dopamine transporter (DAT; Ki ≈ 0.60 µM) and norepinephrine transporter (NET; Ki = 0.07–0.10 µM), with negligible serotonin transporter affinity (Ki = 20–40 µM)supported
Amphetamine Ki values: NET = 0.07-0.1 μM, DAT ≈ 0.6 μM, SERT = 20-40 μM. Amphetamine and methamphetamine are most potent at NET, 5-9 fold less potent at DAT, and 200-500 fold less potent at SERT. pmid:16515684
Intracellular TAAR1 agonism triggers transporter internalization, amplifying monoamine effluxsupported
Amphetamine causes endocytosis of NET and EAAT3 via intracellular TAAR1 activation and RhoA signaling in norepinephrine neurons. s11064-019-02939-6
The resulting catecholamine surge produces dose-dependent cognitive enhancement, psychomotor activation, euphoria, and sympathomimetic arousal — effects modulated substantially by individual DAT gene polymorphisms and by environmental context.supported
DAT polymorphism rs460000 C/C genotype showed 2-fold higher ratings of stimulation and euphoria. Provides dose-response and subjective effects data for d-amphetamine in healthy subjects. s10519-009-9331-7
Cardiovascular toxicity constitutes the principal safety concern: chronic use elevates blood pressure, and an FDA black box warning notes sudden cardiac death risk in patients with structural cardiac abnormalitiespartially supported
Cochrane review: daily ingestion of amphetamines (prescribed for ADHD and other diagnoses) has potential to increase blood pressure; long-term benefit vs. harm remains uncertain. 14651858.cd007896.pub4
Tolerance develops through D2 receptor downregulation, DAT expression changes, and monoamine store depletion; paradoxically, intermittent dosing can produce behavioral sensitization via VMAT2 redistributionsupported
Supports hypothesis that VMAT modulates AMPH-sensitization via redistribution of intraneuronal DA pools. j.brainres.2025.149848
Dextroamphetamine carries high psychological dependence liability (Schedule II, US) and can precipitate amphetamine psychosis with chronic high-dose usesupported
Review of amphetamine neurotoxicity and behavioral sensitization as models of amphetamine psychosis. pmid:3527341
comparative-pharmacology5 · 5 ok
Thomas et al. (2004) confirmed that both d-amphetamine and d-methamphetamine cause microglial activation as a marker of striatal neurotoxicity at high doses, though methamphetamine's threshold for neurotoxicity is lower.partially supported
D-amphetamine (along with D-methamphetamine, MDMA, p-chloroamphetamine) causes microglial activation in striatum, linked to dopamine nerve terminal damage. pmid:15337264
D-amphetamine has negligible SERT affinity (Ki = 20–40 µM) while mdma possesses high SERT affinity, producing its characteristic empathogenic and entactogenic effectssupported
Amphetamine Ki values: SERT = 20-40 μM. Amphetamine and methamphetamine are most potent at NET... 200-500 fold less potent at SERT. pmid:16515684
D-amphetamine is classified as a 'DA-preferential releasing agent' while MDMA functions as a 'mixed DA/5-HT releasing agent'.supported
Drugs with equipotent DA/5-HT substrate activity have minimal abuse liability. Amphetamine described as a DA-preferential releaser with high abuse liability. pmid:17017961
Cocaine inhibits all three monoamine transporters approximately equally through reuptake blockade, whereas d-amphetamine acts through reverse transport with strong NET/DAT selectivitysupported
Amphetamine and methamphetamine are most potent at NET, 5-9 fold less potent at DAT, and 200-500 fold less potent at SERT. pmid:16515684
Trotti et al. (2024) conducted the first direct head-to-head randomized trial comparing amphetamine-dextroamphetamine with modafinil for narcolepsy type 2 and idiopathic hypersomniasupported
Randomized non-inferiority trial comparing modafinil vs amphetamine-dextroamphetamine in narcolepsy type 2 and idiopathic hypersomnia. s40263-024-01122-y
receptor-pharmacology5 · 4 ok
Binding affinity data from Han and Gu (2006), determined using human transporter-transfected HEK-293 cells:supported
Amphetamine Ki values: NET = 0.07-0.1 μM, DAT ≈ 0.6 μM, SERT = 20-40 μM. pmid:16515684
SERT affinity is negligible at therapeutic concentrations, rendering serotonergic effects clinically insignificant under normal dosing conditions.supported
Amphetamine... 200-500 fold less potent at SERT. pmid:16515684
Rothman and Baumann (2006) characterize d-amphetamine as a 'DA-preferential releasing agent' — its reinforcing and abuse-related properties correlate more strongly with DAT-mediated dopamine release than with SERT-mediated serotonin releasesupported
Amphetamine described as a DA-preferential releaser with high abuse liability. pmid:17017961
This classification distinguishes amphetamine from mdma (which has high SERT affinity and prominent serotonergic phenomenology) and from cocaine (which inhibits all three transporters approximately equally).supported
Amphetamine and methamphetamine are most potent at NET, 5-9 fold less potent at DAT, and 200-500 fold less potent at SERT. pmid:16515684
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
pharmacokinetic-detail3 · 3 ok
The transdermal delivery system (d-ATS) provides sustained release over 9 hours with dose-proportional pharmacokinetics at patch strengths of 5, 10, 15, and 20 mg.partially supported
Phase 2 RCT of d-ATS patches (5-20 mg) vs placebo in children/adolescents 6-17 with ADHD. Onset at 2h, duration through 12h. cap.2021.0107
Controlled PK data derive from lisdexamfetamine intranasal studies rather than pure dextroamphetamine insufflationsupported
Pharmacokinetics of d-amphetamine derived from lisdexamfetamine after intranasal vs oral administration. 11588190-000000000-00000
Inter-individual variability in subjective response is partly attributable to DAT gene (SLC6A3) polymorphisms — individuals with the C/C genotype at rs460000 demonstrate approximately 2× higher peak plasma-correlated euphoria and stimulation responses at equivalent doses.supported
DAT polymorphism rs460000 C/C genotype showed 2-fold higher ratings of stimulation and euphoria. s10519-009-9331-7
effects-overview1 · 1 ok
Individual response varies dramatically with DAT gene polymorphisms — identical doses produce primarily cognitive enhancement in some users and pronounced euphoria in otherssupported
DAT polymorphism rs460000 C/C genotype showed 2-fold higher ratings of stimulation and euphoria. s10519-009-9331-7